Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M; PROTECTION AMI Investigators. Lincoff AM, et al. Among authors: aylward p. Eur Heart J. 2014 Oct 1;35(37):2516-23. doi: 10.1093/eurheartj/ehu177. Epub 2014 May 5. Eur Heart J. 2014. PMID: 24796339 Clinical Trial.
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM. White HD, et al. Among authors: aylward pe. Am Heart J. 2006 Dec;152(6):1042-50. doi: 10.1016/j.ahj.2006.08.002. Am Heart J. 2006. PMID: 17161049 Clinical Trial.
Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2.
Edmond JJ, French JK, Aylward PE, Wong CK, Stewart RA, Williams BF, De Pasquale CG, O'connell RL, Van den Berg K, Van de Werf FJ, Simes RJ, White HD; HERO-2 Investigators. Edmond JJ, et al. Among authors: aylward pe. Eur Heart J. 2007 Jun;28(12):1418-24. doi: 10.1093/eurheartj/ehm087. Epub 2007 May 11. Eur Heart J. 2007. PMID: 17496286 Clinical Trial.
Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial.
Wong CK, Gao W, Stewart RA, French JK, Aylward PE, White HD. Wong CK, et al. Among authors: aylward pe. Heart. 2009 Feb;95(4):276-82. doi: 10.1136/hrt.2008.146365. Epub 2008 Dec 15. Heart. 2009. PMID: 19074924 Clinical Trial.
296 results